Medium- and Long-Term Outcomes of Autologous Fat Grafting to Hands and Feet for Patients With Raynaud Phenomenon.
Journal
Annals of plastic surgery
ISSN: 1536-3708
Titre abrégé: Ann Plast Surg
Pays: United States
ID NLM: 7805336
Informations de publication
Date de publication:
01 Mar 2024
01 Mar 2024
Historique:
medline:
23
2
2024
pubmed:
23
2
2024
entrez:
23
2
2024
Statut:
ppublish
Résumé
Autologous fat grafting (AFG) has emerged as a promising treatment option for Raynaud phenomenon. However, existing studies are limited by short follow-up, and there is little evidence regarding predictive factors for successful outcomes. A retrospective chart review and standardized phone interviews were performed for all patients (n = 17, 65% response rate) treated with AFG to the hands or feet at our institution for primary or secondary Raynaud from 2010 to 2021. Each occurrence of AFG was defined as a separate surgery (n = 23), with an average follow-up of 3.7 years. At follow-up, patients reported a 31% reduction in cold attack frequency, a 45% reduction in the intensity of individual attacks, a 29% reduction in the duration of attacks, and a 40% improvement in overall Raynaud Condition Score (P < 0.01). Although initial AFG to an extremity significantly improved symptoms, subsequent attempts were not shown to statistically improve outcomes. Digital ulcers were present in 65% of cases, and AFG resulted in ulcer healing in 87% of those cases. Median duration of maximum symptom relief was 1 year postoperatively, with 74% of patients reporting diminishing symptom relief by 4 years postoperatively. Those with a BMI ≥25, with primary Raynaud phenomenon or without preoperative ulcers experienced significantly longer symptom relief (P < 0.05). Average patient satisfaction was 7.7 of 10, and 91% would recommend the procedure to others. Autologous fat grafting is an effective, albeit sometimes temporary, treatment for Raynaud and digital ulcers. Certain patients may be more likely to experience lasting symptom relief beyond 1 year.
Sections du résumé
BACKGROUND
BACKGROUND
Autologous fat grafting (AFG) has emerged as a promising treatment option for Raynaud phenomenon. However, existing studies are limited by short follow-up, and there is little evidence regarding predictive factors for successful outcomes.
METHODS
METHODS
A retrospective chart review and standardized phone interviews were performed for all patients (n = 17, 65% response rate) treated with AFG to the hands or feet at our institution for primary or secondary Raynaud from 2010 to 2021. Each occurrence of AFG was defined as a separate surgery (n = 23), with an average follow-up of 3.7 years.
RESULTS
RESULTS
At follow-up, patients reported a 31% reduction in cold attack frequency, a 45% reduction in the intensity of individual attacks, a 29% reduction in the duration of attacks, and a 40% improvement in overall Raynaud Condition Score (P < 0.01). Although initial AFG to an extremity significantly improved symptoms, subsequent attempts were not shown to statistically improve outcomes. Digital ulcers were present in 65% of cases, and AFG resulted in ulcer healing in 87% of those cases. Median duration of maximum symptom relief was 1 year postoperatively, with 74% of patients reporting diminishing symptom relief by 4 years postoperatively. Those with a BMI ≥25, with primary Raynaud phenomenon or without preoperative ulcers experienced significantly longer symptom relief (P < 0.05). Average patient satisfaction was 7.7 of 10, and 91% would recommend the procedure to others.
CONCLUSIONS
CONCLUSIONS
Autologous fat grafting is an effective, albeit sometimes temporary, treatment for Raynaud and digital ulcers. Certain patients may be more likely to experience lasting symptom relief beyond 1 year.
Identifiants
pubmed: 38394270
doi: 10.1097/SAP.0000000000003752
pii: 00000637-202403000-00008
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
287-293Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
Financial disclosure statement: The authors have no financial conflicts of interest to disclose.
Références
Garner R, Kumari R, Lanyon P, et al. Prevalence, risk factors and associations of primary Raynaud's phenomenon: systematic review and meta-analysis of observational studies. BMJ Open. 2015;5:e006389.
Haque A, Hughes M. Raynaud's phenomenon. Clin Med (Lond). 2020;20:580–587.
Pauling JD, Hughes M, Pope JE. Raynaud's phenomenon—an update on diagnosis, classification and management. Clin Rheumatol. 2019;38:3317–3330.
Roustit M, Blaise S, Allanore Y, et al. Phosphodiesterase-5 inhibitors for the treatment of secondary Raynaud's phenomenon: systematic review and meta-analysis of randomised trials. Ann Rheum Dis. 2013;72:1696–1699.
Wood HM, Ernst ME. Renin-angiotensin system mediators and Raynaud's phenomenon. Ann Pharmacother. 2006;40:1998–2002.
Su KY, Sharma M, Kim HJ, et al. Vasodilators for primary Raynaud's phenomenon. Cochrane Database Syst Rev. 2021;5:CD006687.
Satteson ES, Chung MP, Chung LS, et al. Microvascular hand surgery for digital ischemia in scleroderma. J Scleroderma Relat Disord. 2020;5:130–136.
Momeni A, Sorice SC, Valenzuela A, et al. Surgical treatment of systemic sclerosis—is it justified to offer peripheral sympathectomy earlier in the disease process? Microsurgery. 2015;35:441–446.
Bello RJ, Cooney CM, Melamed E, et al. The therapeutic efficacy of botulinum toxin in treating scleroderma-associated Raynaud's phenomenon: a randomized, double-blind, placebo-controlled clinical trial. Arthritis Rheumatol. 2017;69:1661–1669.
Bank J, Fuller SM, Henry GI, et al. Fat grafting to the hand in patients with Raynaud phenomenon: a novel therapeutic modality. Plast Reconstr Surg. 2014;133:1109–1118.
Del Papa N, Di Luca G, Andracco R, et al. Regional grafting of autologous adipose tissue is effective in inducing prompt healing of indolent digital ulcers in patients with systemic sclerosis: results of a monocentric randomized controlled study. Arthritis Res Ther. 2019;21:7.
Pignatti M, Spinella A, Cocchiara E, et al. Autologous fat grafting for the oral and digital complications of systemic sclerosis: results of a prospective study. Aesthetic Plast Surg. 2020;44:1820–1832.
Granel B, Daumas A, Jouve E, et al. Safety, tolerability and potential efficacy of injection of autologous adipose-derived stromal vascular fraction in the fingers of patients with systemic sclerosis: an open-label phase I trial. Ann Rheum Dis. 2015;74:2175–2182.
Guillaume-Jugnot P, Daumas A, Magalon J, et al. Autologous adipose-derived stromal vascular fraction in patients with systemic sclerosis: 12-month follow-up. Rheumatology. 2016;55:301–306.
Strong AL, Adidharma W, Brown OH, et al. Fat grafting subjectively improves facial skin elasticity and hand function of scleroderma patients. Plast Reconstr Surg Glob Open. 2021;9:e3373.
Strong AL, Rubin JP, Kozlow JH, et al. Fat grafting for the treatment of scleroderma. Plast Reconstr Surg. 2019;144:1498–1507.
Bene MD, Pozzi MR, Rovati L, et al. Autologous fat grafting for scleroderma-induced digital ulcers. An effective technique in patients with systemic sclerosis. Handchir Mikrochir Plast Chir. 2014;46:242–247.
Merkel PA, Herlyn K, Martin RW, et al. Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon. Arthritis Rheum. 2002;46:2410–2420.
Steen VD, Medsger TA. The value of the health assessment questionnaire and special patient-generated scales to demonstrate change in systemic sclerosis patients over time. Arthritis Rheum. 1997;40:1984–1991.
Ballarini NM, Thomas M, Rosenkranz GK, et al. Subtee: an R package for subgroup treatment effect estimation in clinical trials. J Stat Softw. 2021;99:1–17.
Guo J, Nguyen A, Banyard DA, et al. Stromal vascular fraction: a regenerative reality? Part 2: mechanisms of regenerative action. J Plast Reconstr Aesthet Surg. 2016;69:180–188.
Lindegren A, Schultz I, Sinha I, et al. Autologous fat transplantation alters gene expression patterns related to inflammation and hypoxia in the irradiated human breast. Br J Surg. 2019;106:563–573.
Ejaz A, Epperly MW, Hou W, et al. Adipose-derived stem cell therapy ameliorates ionizing irradiation fibrosis via hepatocyte growth factor-mediated transforming growth factor-β downregulation and recruitment of bone marrow cells. Stem Cells. 2019;37:791–802.
Deptuła M, Brzezicka A, Skoniecka A, et al. Adipose-derived stromal cells for nonhealing wounds: emerging opportunities and challenges. Med Res Rev. 2021;41:2130–2171.
Gentile P, Casella D, Palma E, et al. Engineered fat graft enhanced with adipose-derived stromal vascular fraction cells for regenerative medicine: clinical, histological and instrumental evaluation in breast reconstruction. J Clin Med. 2019;8:504.
Gentile P, Scioli MG, Bielli A, et al. Comparing different nanofat procedures on scars: role of the stromal vascular fraction and its clinical implications. Regen Med. 2017;12:939–952.
Moon KC, Suh HS, Kim KB, et al. Potential of allogeneic adipose-derived stem cell-hydrogel complex for treating diabetic foot ulcers. Diabetes. 2019;68:837–846.
Alaaeddine N, El Atat O, Saliba N, et al. Effect of age and body mass index on the yield of stromal vascular fraction. J Cosmet Dermatol. 2018;17:1233–1239.
Luze H, Schwarz A, Philipp Nischwitz S, et al. Autologous fat grafting in reconstructive breast surgery: clinically relevant factors affecting the graft take. Aesthet Surg J. 2022;42:NP745–NP755.
Rosendahl AH, Schönborn K, Krieg T. Pathophysiology of systemic sclerosis (scleroderma). Kaohsiung J Med Sci. 2022;38:187–195.
Daumas A, Magalon J, Jouve E, et al. Long-term follow-up after autologous adipose-derived stromal vascular fraction injection into fingers in systemic sclerosis patients. Curr Res Transl Med. 2017;65:40–43.
Scuderi N, Ceccarelli S, Onesti MG, et al. Human adipose-derived stromal cells for cell-based therapies in the treatment of systemic sclerosis. Cell Transplant. 2013;22:779–795.
Wilson J, Baker P, Rangan A. Is retrospective application of the Oxford Shoulder Score valid? J Shoulder Elbow Surg. 2009;18:577–580.
Litwin MS, McGuigan KA. Accuracy of recall in health-related quality-of-life assessment among men treated for prostate cancer. J Clin Oncol. 1999;17:2882–2888.
Borrelli MR, Shen AH, Lee GK, et al. Radiation-induced skin fibrosis: pathogenesis, current treatment options, and emerging therapeutics. Ann Plast Surg. 2019;83(4S Suppl 1):S59–S64.